{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-047882","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.839490+00:00","generated_at":"2026-05-25T07:03:11.157566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ","bullets":["FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).","Over 300,000 filled prescriptions launch-to-date, up ~110% since last earnings report.","Q4 net loss $74.5M; non-GAAP adjusted net loss $56.4M vs $46.0M in prior year Q4.","SG&A expenses rose to $290.7M in FY2024 vs $117.9M in FY2023 due to commercial buildout.","Phase 2 EoE trial for VOQUEZNA to begin enrollment in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-047882","json":"https://secwatch.observer/filing/0001193125-25-047882.json","markdown":"https://secwatch.observer/filing/0001193125-25-047882.md","text":"https://secwatch.observer/filing/0001193125-25-047882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/0001193125-25-047882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/d940367d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:03:11.157566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}